MVT 5873

Drug Profile

MVT 5873

Alternative Names: 5B1-(sLeA)-therapeutic; Anti-CA19.9 antibody; anti-sialyl Lewisa antibody; HuMab-5B1; HuMab-5B1 antibody; MVT-5873

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MabVax Therapeutics
  • Developer MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center; Sarah Cannon Research Institute
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer; Colorectal cancer; Pancreatic cancer
  • Preclinical Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 31 Oct 2017 Additional efficacy data from a phase I trial in Pancreatic cancer released by MabVax Therapeutics
  • 31 Oct 2017 Pharmacodynamics data from a preclinical study in cancer released by MabVax Therapeutics
  • 01 Oct 2017 Preclinical trials in Non-small cell lung cancer in USA (IV), before October 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top